Gaudium IVF H1 revenue rose 14.7% while PAT fell 10.5% year on year

Gaudium IVF reported H1 FY27 consolidated revenue from operations of Rs 56.79 crore, up 14.73% year on year, but profit after tax fell 10.53% to Rs 11.19 crore as marketing expenditure and early-stage new-hub fixed costs reduced margins. The company said IVF drove Q2 FY27 revenue growth, while hospital and pharmacy businesses partly offset the cost pressure.

Why did Gaudium IVF's H1 FY27 profit fall despite revenue growth?

Gaudium IVF's H1 FY27 profit fell because its 14.73% revenue increase was outweighed by marketing spending and fixed costs associated with newly rolled-out hubs in early ramp-up. Consolidated revenue rose to Rs 56.79 crore from Rs 49.50 crore in H1 FY26, while earnings before interest, tax, depreciation and amortisation, or EBITDA, excluding other income declined to Rs 15.89 crore from Rs 18.95 crore.

The reduction extended to profit after tax, or PAT, which fell to Rs 11.19 crore from Rs 12.51 crore. PAT margin declined by 556 basis points to 19.70% from 25.26%; one basis point is one-hundredth of a percentage point. Gaudium IVF states that its margin ratios are based on PAT from continuing operations.

The difference between the top line and operating earnings is material: revenue increased by Rs 7.29 crore, while EBITDA decreased by Rs 3.06 crore. Management attributed the compression to its marketing strategy and the high fixed costs of new hubs that were still at an early stage of ramp-up during H1 FY27.

How did Gaudium IVF perform in Q2 FY27?

Gaudium IVF's consolidated Q2 FY27 revenue increased 17.90% year on year to Rs 37.41 crore, while PAT was nearly unchanged at Rs 9.41 crore, up 0.36%. The company said the quarterly revenue growth was driven mainly by the IVF business; Q2 FY26 revenue was Rs 31.73 crore and PAT was Rs 9.38 crore.

EBITDA excluding other income fell 2.13% to Rs 13.47 crore in Q2 FY27 from Rs 13.76 crore a year earlier, even as revenue expanded. EBITDA margin contracted by 737 basis points to 36.00%, while PAT margin declined by 440 basis points to 25.16% from 29.56%, consistent with the costs management identified across the half year.

Q2 FY27 was substantially larger than Q1 FY27, when consolidated revenue was Rs 19.38 crore, EBITDA was Rs 2.42 crore and PAT was Rs 1.78 crore. In Q2, these figures rose to Rs 37.41 crore, Rs 13.47 crore and Rs 9.41 crore respectively, but Q1's 12.51% EBITDA margin and 9.17% PAT margin kept H1 FY27 profitability below H1 FY26 levels.

What expansion costs did Gaudium IVF identify?

Gaudium IVF identified marketing expenditure and the high fixed costs of newly rolled-out hubs as the stated causes of margin pressure in Q2 FY27 and H1 FY27. The presentation does not quantify marketing expense or losses by hub, but says the new locations remain in early ramp-up and therefore carry high fixed costs.

The centre schedule lists South Delhi and Gurgaon as centres commencing in 2026. Each is listed with four beds, one operating theatre and a Level-2 assisted reproductive technology, or ART, facility. The network also includes Srinagar, which commenced in 2024, Bengaluru in 2023 and Mumbai in 2022.

Gaudium IVF said hospital and pharmacy businesses partly offset the marketing and hub-rollout costs in the consolidated Q2 FY27 outcome. It did not disclose separate H1 FY27 revenue, EBITDA or PAT for IVF, hospital and pharmacy operations, so the presentation does not establish the individual profit contribution of those businesses.

How did Gaudium IVF's balance sheet change by September 2026?

Gaudium IVF ended 30 September 2026 with consolidated cash and cash equivalents of Rs 20.49 crore, compared with Rs 8.79 crore at 31 March 2026. Consolidated net worth increased to Rs 163.15 crore from Rs 152.30 crore, while total sources of funds rose to Rs 200.42 crore from Rs 193.10 crore.

Lease-related balances increased over the same period. Non-current lease liabilities rose to Rs 15.29 crore at 30 September 2026 from Rs 1.28 crore at 31 March 2026, and right-of-use assets increased to Rs 20.51 crore from Rs 1.22 crore. The presentation separately identifies new-hub rollout costs as a factor affecting earnings.

Current borrowings declined to Rs 4.80 crore from Rs 23.07 crore between the two balance-sheet dates. Trade receivables also reduced to Rs 45.30 crore from Rs 53.38 crore, while trade payables fell to Rs 7.72 crore from Rs 12.23 crore, alongside the Rs 11.70 crore increase in cash and cash equivalents.

What did Gaudium IVF's H1 FY27 cash flows show?

Gaudium IVF reported consolidated operating cash generation of Rs 19.77 crore for the six months ended 30 September 2026, compared with Rs 2.36 crore in the corresponding prior-year period. Investing cash flow was an inflow of Rs 15.06 crore, compared with an outflow of Rs 5.44 crore a year earlier.

Financing cash flow was an outflow of Rs 23.13 crore in the six months to 30 September 2026, compared with an inflow of Rs 2.49 crore in the prior-year period. The combined movements resulted in a net increase in cash and cash equivalents of Rs 11.70 crore, against a decrease of Rs 59.63 lakh in the corresponding period.

Closing cash and cash equivalents were Rs 20.49 crore at 30 September 2026, following opening cash of Rs 8.79 crore. H1 FY27 PAT of Rs 11.19 crore was below reported operating cash generation of Rs 19.77 crore, but the presentation does not provide a working-capital or non-cash-item reconciliation for the difference.

Conclusion

Gaudium IVF's H1 FY27 results show revenue growth and profit moving in opposite directions: consolidated revenue rose 14.73% to Rs 56.79 crore, while EBITDA declined 16.14% to Rs 15.89 crore and PAT fell 10.53% to Rs 11.19 crore. Management linked the margin decline to marketing expenditure and early-ramp-up fixed costs at new hubs.

The disclosed issue to watch is whether the South Delhi and Gurgaon centres, both listed as commencing in 2026, move beyond their early ramp-up stage. Gaudium IVF has not provided a numerical margin target or timetable, leaving future revenue growth, EBITDA margin and PAT margin as the reported measures of whether the expansion costs are being absorbed.